PUBLIC CONTRACT · 2026
050103852026 - C/ base no cpa 2025_1303 - Ocrelizumab 920 mg/23 ml sol inj fr 23 ml sc
- Contract value
- €1,615,944.60
- Signed on
- 25 September 2026
- Procedure
- Ao abrigo de acordo-quadro (art.º 258.º)
This page lays out the fields published on Portal BASE and says when a field is unavailable. It is not an assessment of the contract's merit, legality or impact.
Record 15733099PUBLISHED SUBJECT
050103852026 - C/ BASE NO CPA 2025_1303 - OCRELIZUMAB 920 MG/23 ML SOL INJ FR 23 ML SC
Parties involved
- Place of performance
- Portugal, Coimbra, Coimbra
- NUTS region
- PT192 - Região de Coimbra
WHO BID
Awardee and competitors
Companies that IMPIC lists as the awardee and as competitors in this procedure.
- Awardee
- ROCHE FARMACÊUTICA E QUÍMICA, LDA. · Tax ID 500233810
Values and timeline
- Contract price
- €1,615,944.60
- Procedure base price
- €1,615,944.60
- Total effective price
- Not reported on Portal BASE
- Publication date
- 6 October 2026
- Award date
- 17 September 2026
- Signing date
- 25 September 2026
- Performance period
- 97 days
The contract price is the value agreed in the contract, not the amount paid.
Procedure and framework
- Contract type
- Aquisição de bens móveis
- Procedure type
- Ao abrigo de acordo-quadro (art.º 258.º)
- Award criterion
- Monofator
- CPV code
- 33600000-6 - Produtos farmacêuticos
- Legal basis
- Artigo 258.º do Código dos Contratos Públicos
- Regime
- Código dos Contratos Públicos (DL111-B/2017) e Lei n.º 30/2021, de 21.05
- Framework agreement
- 1303/2025 - Concurso público internacional para formação do acordo quadro de medicamentos diversos na área da saúde
- Centralised procedure
- No
- Environmental criterion
- No
- Notice
- Not stated
- Procedure identifier
- 11482790
Compare with other contracts
Search the same body, supplier, place or type of service to understand the context of the published index.